We collaborate with you to develop therapeutic and medical technology aimed at solving challenges like cancer, disease detection, autoimmunity, allergies, infectious diseases and other metabolic, cardiovascular and neurodegenerative disorders. Our team of scientists also support clients focused on antibody and vaccine development.
We help develop products in diverse areas of immunology including:
- Cancer immunotherapy
- Detection systems
- Autoimmune disease
- Immune modulation
- Antibody technology
- Medical devices
- Antibody technology
Applying our commercialization experience and strong immunology background, we’ll partner with you to solve significant immunology-related health issues.
We apply a combination of immunology-based techniques to facilitate the progress of new diagnostics and treatments to manage a wide array of diseases.
We have the expertise to support different aspects of immunology product development including: gene therapy, cytokines, checkpoint inhibitors, cancer vaccines, adjuvants, and tumor-infecting viruses. Our scientists are also knowledgeable in applying other techniques like immune checkpoint therapy and adoptive cell transfer. We also develop high-quality antibodies to use in targeted therapy
What we’ve done
We’ve proven our ability to expertly develop products and commercialize technology. Our collaborative approach keeps you informed and your project on track.
Some examples of immunology products we’ve helped develop include:
Diagnostic for detection of autoimmune disease
We used our immunology expertise to develop a sensitive diagnostic test based on detecting the presence of autoimmune antibody is serum.
Antibody engineering for CAR-T
We optimized an adaptable CAR-T therapy system shown to target tumor cells based on the rapid detection of surface antigens. We established cell proliferation assays and FACS analysis of cell surface markers to demonstrate effective tumor cell killing by the novel therapeutic.
Support Clinical Trials
Developed in vitro assays to demonstrate dendritic cell potency and quantified the activation of cytotoxic T cells using patient-derived antigen-presenting cells and peripheral blood mononuclear cells in order to support Phase II Clinical Trials.
Method development for tumor imaging molecules
Controlling the serum half-life was key for custom F(ab) molecules and diabodies that we prepared for use in tumor imaging studies. These antibody fragments were specifically labeled with proprietary PEGs to precisely regulate the clearance rate in vivo. These conjugates were then used for successful tumor imaging studies.